Principal Investigators:
Chaim Lotan MD, Morris Mosseri MD

Sponsor:
Wyeth Ayerst Research

Monitor
Icon

Abstract
The primary objectives of this study are to evaluate the efficacy of recombinant P-selectin glycoprotein ligand-Ig (rPSGL-Ig) on impaired tissue perfusion and on infarct size after thrombolysis with the use of a positron emission tomography (PET) scan. The secondary objectives are to evaluate the safety of rPSGL-Ig in combination with thrombolytic therapy and to evaluate the effect on accelerating clot lysis in the infarct related epicardial coronary artery, on improving coronary blood flow reserve and preserving myocardial function at follow-up when rPSGL-Ig is used in combination with thrombolytic therapy in patients with acute myocardial infarction. In addition, dose-ranging information will be obtained. Status
On hold